Cam­bri­an's an­ti-ag­ing mis­sion ex­pands with new fi­brot­ic dis­ease biotech

Cam­bri­an Bio­Phar­ma has a new pipeline com­pa­ny fo­cused on a dis­ease tar­get that hasn’t met much suc­cess.

The new drug de­vel­op­er, called Is­ter­ian Biotech, emerged …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER